Every Form 4 that Anika Therapeutics Inc (ANIK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANIK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIK filings page.
Anika Therapeutics, Inc. director Gary P. Fischetti reported open-market purchases of company stock. On August 3 and 4, 2026, he bought 1,000 shares of Common Stock on each date at per-share prices of $20.745 and $20.315, respectively, for a total of 2,000 shares acquired directly.
Fischetti Gary P reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Gary P. Fischetti received a grant of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award carried no cash purchase price and increases his direct holdings to 52,015 shares after the grant.
Each RSU represents a right to receive one share of Anika Therapeutics common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with long-term shareholder interests.
HENNEMAN JOHN B III reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director John B. Henneman III received an equity award of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award was granted at no cash cost and increases his direct holdings to 65,273 common shares.
Each RSU represents a contingent right to receive one share of Anika’s common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with long-term shareholder outcomes.
Richard Stephen reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Richard Stephen received a grant of 10,402 restricted stock units on June 18, 2026. Each RSU equals one share of common stock and vests in full on the earlier of the 2027 annual shareholder meeting or June 18, 2027. Following this award, he holds 58,273 shares directly.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award was made on June 18, 2026 at no cash cost to him and increased his direct holdings to 30,805 shares.
Each RSU represents a contingent right to receive one share of Anika Therapeutics common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with future company performance.
CONLEY SHERYL L reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Sheryl L. Conley reported an equity award of restricted stock units. She received 10,402 RSUs of common stock as a grant, with no cash paid per share. Each RSU represents the right to receive one share of common stock.
The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027. After this award, Conley directly holds 52,970 shares of Anika Therapeutics common stock, reflecting her total direct ownership reported in this filing.
Anika Therapeutics, Inc. President and CEO Stephen D. Griffin reported the vesting of 12,840 restricted stock units on June 3, 2026, which converted into 12,840 shares of common stock at no cash cost as the second of three equal annual installments from a 38,520-RSU grant awarded on June 3, 2024.
To satisfy tax withholding obligations on this vesting, the issuer retained 3,769 shares at $14.41 per share. After these transactions, Griffin directly holds 45,973 shares of Anika common stock, including 739 shares acquired on May 14, 2026 under the company’s Employee Stock Purchase Plan.
Anika Therapeutics, Inc. director John B. Henneman III reported an open-market purchase of 5,000 shares of common stock at a weighted average price of $14.6639 per share. Following this transaction, he directly holds 54,871 shares. The shares were bought in multiple trades between $14.595 and $14.75.
Anika Therapeutics, Inc. reported that President and CEO Stephen D. Griffin made an open-market purchase of the company’s common stock. On April 30, 2026, he bought 12,200 shares at a weighted average price of $12.2853 per share. Following this transaction, he directly owns 36,163 shares of Anika Therapeutics common stock. The filing notes that the shares were acquired in multiple trades at prices ranging from $12.235 to $12.30 per share.
Anika Therapeutics SVP, CAO & Treasurer Ian McLeod received new equity awards. On March 19, 2026, he was granted 13,097 Restricted Stock Units and a separate 11,194 RSU award, each representing a contingent right to one share of common stock or cash on vesting. He also received 17,663 Premium Priced Stock Appreciation Rights with a $15.60 exercise price, vesting in three annual installments starting March 19, 2027, and expiring on March 19, 2036.
Anika Therapeutics EVP and General Counsel David Colleran reported equity award vesting and related tax withholding, not open-market trading. On March 14, 2026 and March 15, 2026, he exercised a total of 15,837 restricted stock units into the same number of common shares at $0.00 per share.
He also received a grant or award of 4,694 common shares. To cover tax obligations on these RSU and PSU vestings, 4,168 and 1,893 shares of common stock were withheld at $14.20 per share. Following these transactions, Colleran directly holds 67,570 shares of Anika Therapeutics common stock, with additional RSU awards continuing to vest over time as indicated in the footnotes.
Anika Therapeutics President and CEO Stephen D. Griffin reported equity compensation activity tied to vesting restricted stock units. On March 14, 2026, he exercised 12,824 restricted stock units, receiving 12,824 shares of common stock at a stated exercise price of $0.00 per share.
On the same date, he also acquired 6,412 shares of common stock as a grant or award, and 5,944 shares were withheld by the company at $14.20 per share to cover tax obligations related to vested RSUs and PSUs. Following these transactions, Griffin directly owns 23,963 shares of Anika Therapeutics common stock.
Anika Therapeutics director Cheryl R. Blanchard reported compensation-related stock activity involving restricted stock units (RSUs) and performance-based RSUs (PSUs). On March 14, 2026, 24,519 RSUs and 24,519 PSUs vested and were converted into common shares, and she also received a grant of 24,520 common shares.
On March 15, 2026, an additional 25,131 RSUs vested and were converted into 25,131 common shares. To cover related tax withholding obligations, the company retained 14,728 shares on March 14 and 12,104 shares on March 15 at a price of $14.20 per share, rather than selling shares in the open market.
Following these transactions, Blanchard directly holds 258,788 common shares and indirectly holds 11,742 shares through a revocable trust of which she is the sole trustee and a beneficiary. The transactions reflect equity awards vesting and associated tax withholding, not open-market purchases or sales.
Anika Therapeutics SVP, CAO & Treasurer Ian McLeod reported compensation-related stock activity, mainly from vesting of prior equity awards. On March 14, 2026, he exercised restricted stock units for 3,774 shares of common stock and received an additional 1,161 shares as a grant or award. On March 15, 2026, he exercised further restricted stock units for 2,658 shares. To cover tax withholding obligations tied to these RSU and PSU vestings, the issuer retained 1,449 shares on March 14 and 781 shares on March 15 at $14.20 per share, which are coded as tax-withholding dispositions rather than open-market sales. Following these transactions, McLeod directly holds 24,107 shares of Anika common stock and 2,659 restricted stock units.
Anika Therapeutics EVP and General Counsel David Colleran reported routine equity compensation activity tied to previously granted restricted stock units (RSUs). On March 9, 2026, 5,465 RSUs from a March 9, 2023 grant vested and were converted into an equal number of common shares at no exercise price.
To cover tax withholding on the vesting, 1,919 common shares were retained by the company at a price of $14.96 per share, as a tax-withholding disposition rather than a market sale. After these transactions, Colleran directly holds 53,100 shares of Anika Therapeutics common stock.
Anika Therapeutics director Cheryl R. Blanchard reported the vesting of 20,001 restricted stock units into common shares. Each RSU converts into one share of common stock, and this represents the third and final installment of a 60,004-unit award granted on March 9, 2023.
Of the vested shares, 5,871 were withheld by the company at $14.96 per share to cover tax obligations, leaving a net increase of 14,130 shares. Following these transactions, Blanchard holds 211,450 shares directly and an additional 11,742 shares indirectly through a revocable trust of which she is the sole trustee and a beneficiary.
Anika Therapeutics, Inc. SVP, CAO & Treasurer Ian McLeod completed the final vesting of a prior RSU grant and related tax withholding. On March 9, 2026, 2,197 restricted stock units converted into 2,197 shares of common stock, representing the third and final installment of a 6,590‑RSU award granted on March 9, 2023. To cover tax obligations on this vesting, 639 shares were retained by the company at a price of $14.96 per share, leaving a net 1,558 shares from this tranche. After these transactions, McLeod directly holds 18,744 shares of Anika Therapeutics common stock.
Anika Therapeutics President and CEO Stephen D. Griffin, who is also a director, reported new equity awards effective February 1, 2026. He was granted 310,207 stock appreciation rights with an exercise price of $9.23 and 130,402 restricted stock units.
Both the stock appreciation rights and RSUs were awarded at no cash cost to him and are granted under Anika’s 2017 Omnibus Incentive Plan. They vest in three equal annual installments, beginning on February 1, 2027, conditioned on his continued service.
Following these awards, Griffin directly holds 10,671 shares of Anika common stock, which includes 800 shares acquired on November 14, 2025 through the company’s Employee Stock Purchase Plan. The stock appreciation rights may be settled in cash, shares, or a combination, and each RSU represents the right to one share or the cash equivalent on vesting.